Vitiligo Treatment in Bangkok: Ruxolitinib, NB-UVB, and Melanocyte Transplant

Vitiligo is a chronic autoimmune depigmenting disorder affecting roughly 0.5-2% of the global population, including a substantial number of Thai and South-East-Asian patients. At Siam Dermatology in Bangkok, our English-speaking board-certified dermatologists (Faculty, Institute of Dermatology) offer comprehensive evaluation and modern combination therapy aligned with the 2022 European Vitiligo Task Force guidelines and the FDA approvals of topical ruxolitinib (2022) and oral ritlecitinib for related conditions. We classify each patient as segmental (unilateral, follows Blaschko lines, stable, limited area) or non-segmental (symmetric, generalized, active vs stable) before tailoring therapy.

Diagnosis and Activity Assessment: VASI + VES + Wood's lamp

Diagnosis is clinical, confirmed with Wood's lamp examination (depigmented chalk-white fluorescence). We document baseline severity with the Vitiligo Area Scoring Index (VASI) and Vitiligo Extent Score (VES), and photograph involved sites under standardized lighting for accurate follow-up. Activity signs (confetti depigmentation, trichrome, Koebner phenomenon, hypochromic borders) indicate aggressive disease that warrants prompt treatment to prevent expansion. Screen for associated autoimmune conditions: TSH (autoimmune thyroiditis 15-20%), CBC (pernicious anemia), fasting glucose (type 1 DM), ANA (lupus overlap rare), and 25-OH vitamin D.

Medical Therapy: Ruxolitinib + Tacrolimus + Topical Steroid

First-line topical (small-area facial/body): Ruxolitinib 1.5% cream BID (Opzelura, JAK1/2 inhibitor, FDA-approved for non-segmental vitiligo ≥3 mo) — around 30% achieve F-VASI75 by week 24. Topical tacrolimus 0.1% ointment BID is effective on face/neck/genitals and safe for long-term use. High-potency topical steroid (clobetasol/mometasone) BID for 2-3 months with monthly review (atrophy risk — use intermittent schedule). For widespread non-segmental disease, we add oral mini-pulse betamethasone 5mg twice weekly to halt activity within 2-3 months, then taper. Anti-oxidants (Polypodium leucotomos, vitamin E, alpha-lipoic acid) may serve as adjunct.

NB-UVB 308nm Phototherapy and Surgical Options

Narrowband UVB (311 nm whole-body cabin) or 308 nm excimer (focal) is the cornerstone for moderate-to-extensive disease: 2-3 sessions per week, expect 50% re-pigmentation by 6 months on responsive sites (face > trunk > extremities > acral/lips). Combination with topical agents improves outcomes by 20-30%. For stable segmental or refractory focal vitiligo (no Koebner for ≥1 year): surgical melanocyte transplant — mini-punch grafting, suction blister grafting, or non-cultured epidermal cell suspension (MKTP) — can be transformative. Psychological support and counseling are integral; we coordinate with mental-health partners. Sunscreen SPF 50+ daily protects depigmented areas and reduces contrast.

Q: Can vitiligo be cured? — No, but re-pigmentation is achievable in many patients with combination therapy. Face responds best; acral and lips least. Q: Is Opzelura (ruxolitinib) available in Thailand? — Yes, on a controlled-import basis. We assist with proper procurement. Q: How long does treatment take? — Visible re-pigmentation typically begins at 3-4 months; significant response at 6-9 months. Lifelong maintenance often required. Q: Do you accept international patients? — Yes. We routinely treat travelers, expats, and medical tourists with English-language consultations.

📞 Book at Siam Dermatology — LINE @dr.patskinclinic | Call +66 61 448 7000